Rush University Medical Center is among the backers of Transcarent’s series C round, which pushed the company’s overall financing to $298m.
Transcarent, a US-based operator of a personalised healthcare platform for employers, secured $200m in a series C round on Tuesday from a consortium featuring Rush University Medical Center, the teaching hospital of Rush University.
Kinnevik and Human Capital co-led the round, with participation from health systems Northwell Health and Intermountain Healthcare, pharmaceutical firm Merck & Co’s Global Healthcare Innovation Fund, Ally Bridge, General Catalyst, 7wireVentures, Alta Partners, Jove Equity Partners, Threshold Ventures and GreatPoint Ventures.
Transcarent runs a healthcare platform for self-insured employers, allowing to manage care for their staff and dependents. The company does not generally hold members responsible for co-pays or co-insurance.
Glen Tullman, chief executive of Transcarent, said: “At Transcarent, we have created a new and different health and care experience that puts consumers back in charge and is simply better aligned for employers, employees and their families, and the providers who deliver high-quality care in this…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
